SCHEMBL2034664

SCHEMBL2034664

CC[C@@H](C)[C@H](NC)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.50
FPR2 P25090 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
MME P08473 2/20 0.42
ACE P12821 2/20 0.42
CPA1 P15085 2/20 0.42
ACE2 Q9BYF1 2/20 0.42
CA2 P00918 2/20 0.41
CA1 P00915 1/20 0.41
ENPEP Q07075 2/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203221 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL203222 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL2034259 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL43380 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL43381 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL18560091 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL288609 1.00 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
Hydrochloric Acid SCHEMBL17113018 0.98 ALDH1A1 (0.57) ALDH1A1L3MBTL1FPR2MEN1KMT2A
Hydrochloric Acid SCHEMBL17113020 0.98 ALDH1A1 (0.57) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL12611984 0.92 ALDH1A1 (0.52) ALDH1A1L3MBTL1FPR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3478311-B1 STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION UNIV CALIFORNIA (US) 2026-05-27 EP disclosed
EP-3596102-B1 STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK FIBRILLIZATION SEGMENT UNIV CALIFORNIA (US) 2025-09-10 EP disclosed
EP-4603105-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-20 EP disclosed
CN-120202211-A Cyclic compounds having selective KRAS inhibition over HRAS and NRAS 中外制药株式会社 2025-06-24 CN disclosed
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-16 US disclosed
WO-2024101402-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS 中外製薬株式会社 2024-05-16 WO disclosed
EP-4309741-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-01-24 EP disclosed
CN-116650617-A Structure-based peptide inhibitors of alpha-synuclein aggregation 加利福尼亚大学董事会 2023-08-29 CN disclosed
US-20230069905-A1 STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 US disclosed
WO-2022234853-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS 中外製薬株式会社 2022-11-10 WO disclosed
EP-0815870-A2 Composition for prohylaxis or treatment of cerebral infarction Takeda Chemical Industries, Ltd. (JP) 1998-01-07 EP disclosed
EP-0581429-B1 Process for synthesizing cyclic depsipeptides TAKARA SHUZO CO (JP) 1997-09-03 EP disclosed
EP-0528312-B1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-07-16 EP disclosed
US-5616684-A CYCLIC HEXAPEPTIDE CONTAINING ASPARTIC ACID AND DERIVATIVES, 2-THIENYLGLYCINE, LEUCINE, AND TRYPTOPHAN; ENDOTHELIN RECEPTOR ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-04-01 US disclosed
EP-0714909-A1 Composition for prophylaxis or treatment of pulmonary circulatory diseases Takeda Chemical Industries, Ltd. (JP) 1996-06-05 EP disclosed
EP-0647449-A1 Sustained-release preparation of anti-endothelin substance Takeda Chemical Industries, Ltd. (JP) 1995-04-12 EP disclosed
EP-0626174-A2 Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-30 EP disclosed
EP-0581429-A2 Process for synthesizing cyclic depsipeptides TAKARA SHUZO CO. LTD. (JP) 1994-02-02 EP disclosed
EP-0552417-A1 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-28 EP disclosed
EP-0528312-A2 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230069905-A1 STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION SNCA, PARK7, IAPP ALDH1A1 4530/4885L3MBTL1 395/4885FPR2 2016/4885
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS KRAS, HRAS, NRAS ALDH1A1 4844/4885L3MBTL1 1557/4885FPR2 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.